Cellectis, a clinical-stage biotechnology company specializing in gene-editing and immunotherapies, maintains a highly specialized workforce primarily centered in its European operations. Based on official corporate disclosures and annual regulatory filings, the company operates with a lean and focused team of approximately 229 total employees, comprising a vast majority of full-time research scientists, laboratory technicians, and clinical development professionals alongside a small contingent of part-time staff supporting its advanced therapeutic pipelines.